Legal Representation
Attorney
Julie A. Katz
USPTO Deadlines
Next Deadline
1518 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240402)
Due Date
April 02, 2030
Grace Period Ends
October 02, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 26, 2024 | NURC | C | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | Loading... |
| Oct 24, 2024 | COC. | O | CORRECTION UNDER SECTION 7 - PROCESSED | Loading... |
| Oct 23, 2024 | EROP | I | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | Loading... |
| Oct 23, 2024 | PRAM | O | POST REGISTRATION ACTION MAILED - SEC. 7 | Loading... |
| Oct 22, 2024 | EROP | I | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | Loading... |
| Sep 17, 2024 | PRAM | O | POST REGISTRATION ACTION MAILED - SEC. 7 | Loading... |
| Sep 10, 2024 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Apr 12, 2024 | ES7R | I | TEAS SECTION 7 REQUEST RECEIVED | Loading... |
| Apr 2, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Apr 2, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jan 16, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 16, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 27, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 14, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 14, 2023 | AAUA | E | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | Loading... |
| Dec 13, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 13, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 13, 2023 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 13, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 13, 2023 | IUAA | P | USE AMENDMENT ACCEPTED | Loading... |
| Dec 11, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 25, 2023 | AUPC | I | AMENDMENT TO USE PROCESSING COMPLETE | Loading... |
| Aug 25, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Aug 24, 2023 | EAAU | I | TEAS AMENDMENT OF USE RECEIVED | Loading... |
| Apr 4, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 17, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
oligonucleotides for use in the manufacture of pharmaceuticals; oligopeptides for industrial use; peptide substrates for scientific use; peptides for use in industry and science; peptides for use in research and the manufacture of reagents, diagnostic reagents for science and research use; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; phosphoproteins; proteins for use in industry and science; reagents for research purposes; reagents for scientific use; nucleic acid for diagnostic research; nucleic acid for diagnostic manufacturing
First Use Anywhere:
Apr 30, 2017
First Use in Commerce:
Apr 30, 2017
Class 005
nucleic acid reagents, agents, preparations and substances for medical purposes; nucleic acid sequences for medical and veterinary use; oligonucleotides for diagnostic purposes; oligonucleotides for medical diagnostic purposes; oligonucleotides for medical use; oligonucleotides for pharmaceutical purposes; pharmaceutical preparations against genetic diseases; pharmaceutical preparations against metabolic diseases; pharmaceutical preparations against neurological diseases; pharmaceutical preparations for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, respiratory diseases, cancer, allergies, gynecological diseases, rheumatic diseases, urological diseases, gastroenterological diseases, infectious diseases, eye disease, dermatological diseases, autoimmune diseases, blood diseases, genital diseases, endocrine diseases, intestinal diseases, internal medicine diseases; pharmaceutical preparations for wound healing; reagents for medical purposes; reagents for medical use; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; tumor suppressing agents
First Use Anywhere:
Apr 30, 2017
First Use in Commerce:
Apr 30, 2017
Class 040
biochemical contract manufacturing services; chemical synthesis services, namely, custom synthesis of chemicals for others; custom manufacture of biopharmaceuticals; custom manufacture of pharmaceuticals; custom manufacturing of oligonucleotides; custom modification of antibody; custom modification of protein; development services, namely, design and development of manufacturing processes for others in the field of oligonucleotides; manufacturing, namely, contract manufacturing in the field of oligonucleotides; processing of biopharmaceutical materials for others; processing of chemical reagents; processing of chemicals; processing of medicinal materials; processing of oligonucleotides; processing of peptides; processing of proteins; technical and scientific services, namely, providing technical information in the field of pharmaceutical manufacturing
First Use Anywhere:
Apr 30, 2017
First Use in Commerce:
Apr 30, 2017
Class 042
scientific analysis services for the identification and physical characterization of chemical molecules; scientific and technical services, namely, scientific analysis of industrial installations; scientific and technological services, namely, applied scientific research and development services, namely, conception of development or commercial batches for third parties in the fields of pharmaceuticals and chemicals; scientific and technological services, namely, consulting and assistance in the research and development of chemicals and pharmaceuticals, including experimental and production processes and installations; scientific and technological services, namely, consulting and assistance in the research and development of pharmaceuticals; scientific development services in the field of biochemistry; scientific laboratory services; scientific research and development services for chemicals for the products of third parties, namely, the scientific and technical development of synthetic processes in the field of chemistry and biochemistry; scientific research and development services in the field of pharmaceuticals; scientific research and scientific and technical development in the field of pharmaceutical, chemical, agrochemical and industrial processes; scientific research services, namely, nucleic acid analysis; scientific research services, namely, oligonucleotide analysis; scientific services, namely, scientific analysis allowing the identification and physical characterization of chemical molecules; scientific services, namely, scientific research and industrial analysis in the field of pharmaceuticals, chemicals, and agrochemical and industrial processes; scientific study and research in the area of industrial quality; development of methods of analysis for chemical and pharmaceutical products and bio-organics; scientific study and research services in the field of industrial safety
First Use Anywhere:
Apr 30, 2017
First Use in Commerce:
Apr 30, 2017
Class 044
nucleic acid analysis for medical diagnostic and treatment purposes; oligonucleotide analysis for medical diagnostic and treatment purposes
First Use Anywhere:
Apr 30, 2017
First Use in Commerce:
Apr 30, 2017
Additional Information
Other
In the statement, lines 1-2, "BioSpring Gesellschaft für Biotechnologie GmbH (GERMANY LIMITED LIABILITY COMPANY)" should be deleted, and "BioSpring Gesellschaft für Biotechnologie mbH (GERMANY LIMITED LIABILITY COMPANY)" should be inserted.
Pseudo Mark
BIO SPRING
Classification
International Classes
001
005
040
042
044